Liyan Yang

Dr. Liyan Yang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZWZhonglei Wang
Zhonglei Wang
LYLiyan Yang
Liyan Yang

18 June 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
LYLiyan Yang
Liyan Yang
ZWZhonglei Wang
Zhonglei Wang
As a public health emergency of international concern, the highly contagious coronavirus disease 2019 (COVID-19) pandemic has been identified as a severe threat to the lives of billions of individuals. Lung cancer, a malignant tumor with the highest mortality rate, has brought significant challenges to both human health and economic development. Natural products may play a pivotal role in treating lung diseases. We reviewed published studies relating to natural products, used alone or in combination with US Food and Drug Administration-approved drugs, active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lung cancer from 1 January 2020 to 31 May 2021. A wide range of natural products can be considered promising anti-COVID-19 or anti-lung cancer agents have gained widespread attention, including natural products as monotherapy for the treatment of SARS-CoV-2 (ginkgolic acid, shiraiachrome A, resveratrol, and baicalein) or lung cancer (daurisoline, graveospene A, deguelin, and erianin) or in combination with FDA-approved anti-SARS-CoV-2 agents (cepharanthine plus nelfinavir, linoleic acid plus remdesivir) and anti-lung cancer agents (curcumin and cisplatin, celastrol and gefitinib). Natural products have demonstrated potential value and with the assistance of nanotechnology, combination drug therapies, and the codrug strategy, this “natural remedy” could serve as a starting point for further drug development in treating these lung diseases.

22 December 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ZWZhonglei Wang
Zhonglei Wang
LYLiyan Yang
Liyan Yang
Click on the article title to read more.

19 August 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ZWZhonglei Wang
Zhonglei Wang
NWNing Wang
Ning Wang
LYLiyan Yang
Liyan Yang
XSXian-qing Song
Xian-qing Song
The devastating COVID-19 pandemic has caused more than six million deaths worldwide during the last 2 years. Effective therapeutic agents are greatly needed, yet promising magic bullets still do not exist. Numerous natural products (cordycepin, gallinamide A, plitidepsin, telocinobufagin, and tylophorine) have been widely studied and play a potential function in treating COVID-19. In this paper, we reviewed published studies (from May 2021 to April 2022) relating closely to bioactive natural products (isolated from medicinal plants, animals products, and marine organisms) in COVID-19 therapyin vitroto provide some essential guidance for anti-SARS-CoV-2 drug research and development.

6 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ZWZhonglei Wang
Zhonglei Wang
LYLiyan Yang
Liyan Yang
XSXian-qing Song
Xian-qing Song
GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral bioavailability of GS‐441524 poses a challenge to its anti-SARS-CoV-2 efficacy. Remdesivir, the intravenously administered version (version 1.0) of GS-441524, is the first FDA-approved agent for SARS-CoV-2 treatment. However, clinical trials have presented conflicting evidence on the value of remdesivir in COVID-19. Therefore, oral GS-441524 derivatives (VV116, ATV006, and GS-621763; version 2.0, targeting highly conserved viral RdRp) could be considered as game-changers in treating COVID-19 because oral administration has the potential to maximize clinical benefits, including decreased duration of COVID-19 and reduced post-acute sequelae of SARS-CoV-2 infection, as well as limited side effects such as hepatic accumulation. This review summarizes the current research related to the oral derivatives of GS-441524, and provides important insights into the potential factors underlying the controversial observations regarding the clinical efficacy of remdesivir; overall, it offers an effective launching pad for developing an oral version of GS-441524.

18 December 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ZWZhonglei Wang
Zhonglei Wang
LYLiyan Yang
Liyan Yang
In this era, broad‐spectrum prodrugs with anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) activities are gaining considerable attention owing to their potential clinical benefits and role in combating the fast‐spreading coronavirus disease 2019 (COVID‐19) pandemic. The last 2 years have seen a surge of reports on various broad‐spectrum prodrugs against SARS‐CoV‐2, and in in vitro studies, animal models, and clinical practice. Currently, only remdesivir (with many controversies and limitations) has been approved by the U.S. FDA for the treatment of SARS‐CoV‐2 infection, and additional potent anti‐SARS‐CoV‐2 drugs are urgently required to enrich the defense arsenals. The world has ubiquitously grappled with the COVID‐19 pandemic, and the availability of broad‐spectrum prodrugs provides great hope for us to subdue this global threat. This article reviews promising treatment strategies, antiviral mechanisms, potential benefits, and daunting clinical challenges of anti‐SARS‐CoV‐2 agents to provide some important guidance for future clinical treatment.